Townsend's most recent trade in Lexeo Therapeutics Inc. was a trade of 2,735 Common Stock done at an average price of $4.7 . Disclosure was reported to the exchange on Aug. 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.67 per share. | 18 Aug 2025 | 2,735 | 220,058 | - | 4.7 | 12,767 | Common Stock |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.67 per share. | 18 Aug 2025 | 1,115 | 220,058 | - | 4.7 | 5,205 | Common Stock |
| Unicycive Therapeutics Inc | John W. Townsend | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2025 | 10,000 | 101,557 | - | - | Stock Options | |
| PotlatchDeltic Corp | Ashlee Townsend Cribb | Vice President, Wood Products | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 28 Jul 2025 | 337 | 36,991 (0%) | 0% | 0 | Common Stock | |
| Gogo Inc | Charles C. Townsend | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 4,087 | 202,068 | - | - | Deferred Share Units | |
| Leonardo DRS Inc | Frances Fragos Townsend | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 3,556 | 3,556 | - | - | Restricted Stock Unit | |
| Freeport-McMoRan | Frances Fragos Townsend | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2025 | 4,900 | 124,770 (0%) | 0% | 0 | Common Stock | |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.77 per share. | 16 May 2025 | 1,074 | 221,173 | - | 2.8 | 2,979 | Common Stock |
| Leonardo DRS Inc | Frances Fragos Townsend | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 6,438 | 30,320 | - | 0 | Common Stock | |
| Leonardo DRS Inc | Frances Fragos Townsend | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 6,438 | 0 | - | - | Restricted Stock Unit | |
| Chubb | Frances Fragos Townsend | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 771 | 5,006 (0%) | 0% | - | Common Shares | |
| Chubb | Frances Fragos Townsend | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 292.05 per share. | 15 May 2025 | 180 | 4,826 (0%) | 0% | 292.1 | 52,569 | Common Shares |
| Gogo Inc | Charles C. Townsend | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 6,960 | 197,981 | - | - | Deferred Share Units | |
| Gogo Inc | Charles C. Townsend | Director | Purchase of securities on an exchange or from another person at price $ 6.74 per share. | 17 Mar 2025 | 101,956 | 1,940,688 (2%) | 0% | 6.7 | 687,183 | Common Stock |
| Gogo Inc | Charles C. Townsend | Director | Purchase of securities on an exchange or from another person at price $ 6.57 per share. | 17 Mar 2025 | 98,044 | 1,838,732 (2%) | 0% | 6.6 | 644,149 | Common Stock |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 2.61 per share. | 14 Mar 2025 | 2,128 | 222,247 | - | 2.6 | 5,554 | Common Stock |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.41 per share. | 19 Feb 2025 | 4,326 | 220,119 | - | 4.4 | 19,091 | Common Stock |
| PotlatchDeltic Corp | Ashlee Townsend Cribb | Vice President, Wood Products | Sale of securities on an exchange or to another person at price $ 44.67 per share. | 10 Feb 2025 | 3,454 | 36,779 (0%) | 0% | 44.7 | 154,290 | Common Stock |
| PotlatchDeltic Corp | Ashlee Townsend Cribb | Vice President, Wood Products | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 5,934 | 35,456 (0%) | 0% | 0 | Common Stock | |
| PotlatchDeltic Corp | Ashlee Townsend Cribb | Vice President, Wood Products | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 4,777 | 40,233 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 29.52 per share. | 29 Jan 2025 | 695 | 84,050 (0%) | 0% | 29.5 | 20,519 | Common Stock |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 30.43 per share. | 22 Jan 2025 | 3,323 | 84,745 (0%) | 0% | 30.4 | 101,104 | Common Stock |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 29.96 per share. | 17 Jan 2025 | 2,201 | 88,068 (0%) | 0% | 30.0 | 65,938 | Common Stock |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 28.70 per share. | 13 Jan 2025 | 2,685 | 90,269 (0%) | 0% | 28.7 | 77,065 | Common Stock |
| Capitol Federal Financial | Kent G. Townsend | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 7,516 | 0 | - | - | CFFN Phantom Stock 2021 | |
| Capitol Federal Financial | Kent G. Townsend | Executive Vice President | Sale or transfer of securities back to the company at price $ 5.91 per share. | 31 Dec 2024 | 7,516 | 123,081 (0%) | 0% | 5.9 | 44,420 | CFFN common stock |
| Capitol Federal Financial | Kent G. Townsend | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.33 per share. | 31 Dec 2024 | 7,516 | 130,597 (0%) | 0% | 11.3 | 85,156 | CFFN common stock |
| Gogo Inc | Charles C. Townsend | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 7,416 | 191,021 | - | - | Deferred Share Units | |
| Capitol Federal Financial | Kent G. Townsend | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 4,968 | 4,968 | - | - | CFFN Phantom Stock 2024 | |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.33 per share. | 10 Dec 2024 | 2,500 | 123,195 | - | 2.3 | 5,825 | Common Stock |
| Lexeo Therapeutics Inc | Townsend Richard Nolan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 2,500 | 118,655 | - | - | Stock Option (right to buy) | |
| Lexeo Therapeutics Inc | Nolan Townsend Richard | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 8.20 per share. | 10 Dec 2024 | 2,500 | 120,695 | - | 8.2 | 20,491 | Common Stock |
| Gogo Inc | Townsend C. Charles | Director | 04 Dec 2024 | 100 | 1,740,688 (1%) | 0% | 7.3 | 730 | Common Stock | |
| Leonardo DRS Inc | Frances Townsend Fragos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2024 | 3,572 | 0 | - | - | Restricted Stock Unit | |
| Leonardo DRS Inc | Townsend Frances Fragos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2024 | 3,572 | 23,882 | - | 0 | Common Stock | |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2024 | 2,500 | 121,155 | - | - | Stock Option (right to buy) | |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.82 per share. | 11 Nov 2024 | 2,500 | 120,695 | - | 7.8 | 19,557 | Common Stock |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.33 per share. | 11 Nov 2024 | 2,500 | 123,195 | - | 2.3 | 5,825 | Common Stock |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.33 per share. | 10 Oct 2024 | 5,000 | 125,695 | - | 2.3 | 11,650 | Common Stock |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Oct 2024 | 5,000 | 123,655 | - | - | Stock Option (right to buy) | |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 8.10 per share. | 10 Oct 2024 | 5,000 | 120,695 | - | 8.1 | 40,496 | Common Stock |
| Gogo Inc | Charles C. Townsend | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 8,356 | 183,605 | - | - | Deferred Share Units | |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 5,000 | 128,655 | - | - | Stock Option (right to buy) | |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 10.65 per share. | 10 Sep 2024 | 5,000 | 120,695 | - | 10.7 | 53,274 | Common Stock |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.33 per share. | 10 Sep 2024 | 5,000 | 125,695 | - | 2.3 | 11,650 | Common Stock |
| Unicycive Therapeutics Inc | John W. Townsend | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 40,256 | 915,565 | - | - | Stock Options | |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 11.53 per share. | 12 Aug 2024 | 5,000 | 120,695 | - | 11.5 | 57,635 | Common Stock |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.33 per share. | 12 Aug 2024 | 5,000 | 125,695 | - | 2.3 | 11,650 | Common Stock |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2024 | 5,000 | 133,655 | - | - | Stock Option (right to buy) | |
| PotlatchDeltic Corp | Ashlee Townsend Cribb | Vice President, Wood Products | Sale of securities on an exchange or to another person at price $ 42.94 per share. | 29 Jul 2024 | 2,556 | 30,596 (0%) | 0% | 42.9 | 109,755 | Common Stock |
| PotlatchDeltic Corp | Ashlee Townsend Cribb | Vice President, Wood Products | Sale of securities on an exchange or to another person at price $ 43.40 per share. | 29 Jul 2024 | 1,558 | 29,038 (0%) | 0% | 43.4 | 67,617 | Common Stock |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 17.06 per share. | 10 Jul 2024 | 27,931 | 120,795 | - | 17.1 | 476,503 | Common Stock |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 16.45 per share. | 10 Jul 2024 | 23,622 | 152,073 | - | 16.5 | 388,582 | Common Stock |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2024 | 5,000 | 138,655 | - | - | Stock Option (right to buy) | |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.33 per share. | 10 Jul 2024 | 5,000 | 175,695 | - | 2.3 | 11,650 | Common Stock |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 16.85 per share. | 10 Jul 2024 | 3,347 | 148,726 | - | 16.9 | 56,397 | Common Stock |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 19.06 per share. | 10 Jul 2024 | 100 | 120,695 | - | 19.1 | 1,906 | Common Stock |
| Gogo Inc | Charles C. Townsend | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2024 | 6,237 | 175,249 | - | - | Deferred Share Units | |
| VIZIO Holding Corp Ordinary | Adam Townsend | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 10.63 per share. | 21 Jun 2024 | 32,833 | 704,903 | - | 10.6 | 349,015 | Class A Common Stock |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 5,000 | 143,655 | - | - | Stock Option (right to buy) | |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.33 per share. | 10 Jun 2024 | 5,000 | 175,695 | - | 2.3 | 11,650 | Common Stock |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 17.29 per share. | 10 Jun 2024 | 2,962 | 172,733 | - | 17.3 | 51,213 | Common Stock |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.18 per share. | 10 Jun 2024 | 2,038 | 170,695 | - | 18.2 | 37,051 | Common Stock |
| VIZIO Holding Corp Ordinary | Adam Townsend | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 254,790 | 737,736 | - | 0 | Class A Common Stock | |
| Leonardo DRS Inc | Frances Fragos Townsend | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 9,785 | 20,310 | - | 0 | Common Stock | |
| Leonardo DRS Inc | Frances Fragos Townsend | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 9,785 | 0 | - | - | Restricted Stock Unit | |
| Freeport-McMoRan | Frances Fragos Townsend | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 3,500 | 119,870 (0%) | 0% | 0 | Common Stock | |
| VIZIO Holding Corp Ordinary | Adam Townsend | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 10.53 per share. | 22 May 2024 | 97,110 | 482,562 | - | 10.5 | 1,022,957 | Class A Common Stock |
| Leonardo DRS Inc | Frances Fragos Townsend | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 6,438 | 6,438 | - | - | Restricted Stock Unit | |
| Chubb | Frances Fragos Townsend | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 718 | 4,474 (0%) | 0% | - | Common Shares | |
| Chubb | Frances Fragos Townsend | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 264.88 per share. | 16 May 2024 | 239 | 4,235 (0%) | 0% | 264.9 | 63,306 | Common Shares |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.33 per share. | 13 May 2024 | 5,000 | 175,695 | - | 2.3 | 11,650 | Common Stock |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2024 | 5,000 | 148,655 | - | - | Stock Option (Right to Buy) | |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 13.22 per share. | 13 May 2024 | 5,000 | 170,695 | - | 13.2 | 66,093 | Common Stock |
| Unicycive Therapeutics Inc | John W. Townsend | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2024 | 228,119 | 875,309 | - | - | Stock Options | |
| Gogo Inc | Charles C. Townsend | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2024 | 6,833 | 169,012 | - | - | Deferred Share Units | |
| Gogo Inc | Charles C. Townsend | Director | Purchase of securities on an exchange or from another person at price $ 9.03 per share. | 14 Mar 2024 | 28,857 | 1,740,588 (1%) | 0% | 9.0 | 260,613 | Common Stock |
| Rekor Systems Inc | Anne Townsend | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2024 | 50,000 | 50,000 (0%) | 0% | 0 | Common Stock | |
| Gogo Inc | Charles C. Townsend | Director | Purchase of securities on an exchange or from another person at price $ 8.41 per share. | 29 Feb 2024 | 186,249 | 1,711,731 (1%) | 0% | 8.4 | 1,566,056 | Common Stock |
| Gogo Inc | Charles C. Townsend | Director | Purchase of securities on an exchange or from another person at price $ 8.17 per share. | 29 Feb 2024 | 103,405 | 1,525,482 (1%) | 0% | 8.2 | 844,788 | Common Stock |
| Apellis Pharmaceuticals Inc | Adam Townsend J. | Chief Commercial Officer | 12 Feb 2024 | 1,148 | 92,453 (0%) | 0% | 67.8 | 77,796 | Common Stock | |
| PotlatchDeltic Corp | Ashlee Townsend Cribb | Vice President, Wood Products | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 4,669 | 32,468 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Townsend J. Adam | Chief Commercial Officer | 29 Jan 2024 | 906 | 93,601 (0%) | 0% | 64.1 | 58,109 | Common Stock | |
| Apellis Pharmaceuticals Inc | J. Townsend Adam | Chief Commercial Officer | 22 Jan 2024 | 3,413 | 94,507 (0%) | 0% | 65.0 | 221,831 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 16 Jan 2024 | 34,533 | 34,533 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Townsend J. Adam | Chief Commercial Officer | 16 Jan 2024 | 23,748 | 100,155 (0%) | 0% | 0 | Common Stock | ||
| Apellis Pharmaceuticals Inc | Townsend J. Adam | Chief Commercial Officer | 16 Jan 2024 | 2,235 | 97,920 (0%) | 0% | 66.8 | 149,317 | Common Stock | |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 262,500 | 262,500 | - | - | Stock Option (Right to Buy) | |
| Lexeo Therapeutics Inc | Richard Nolan Townsend | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 43,750 | 170,695 | - | 0 | Common Stock | |
| Capitol Federal Financial | G. Townsend Kent | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.50 per share. | 31 Dec 2023 | 2,654 | 125,735 (0%) | 0% | 12.5 | 33,175 | CFFN common stock |
| Capitol Federal Financial | G. Townsend Kent | Executive Vice President | Sale or transfer of securities back to the company at price $ 6.45 per share. | 31 Dec 2023 | 2,654 | 123,081 (0%) | 0% | 6.4 | 17,118 | CFFN common stock |
| Capitol Federal Financial | G. Kent Townsend | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 2,654 | 0 | - | - | CFFN Phantom Stock 2020 | |
| Gogo Inc | Townsend Charles C. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2023 | 5,923 | 162,179 | - | - | Deferred Share Units | |
| AerSale Corp | Townsend Richard J. | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Dec 2023 | 6,780 | 13,161 | - | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | J. Townsend Adam | Chief Commercial Officer | 01 Dec 2023 | 110,000 | 186,407 (0%) | 0% | 15.1 | 1,659,900 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam Townsend J. | Chief Commercial Officer | 01 Dec 2023 | 110,000 | 172,500 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | J. Townsend Adam | Chief Commercial Officer | 01 Dec 2023 | 67,557 | 118,850 (0%) | 0% | 60.5 | 4,087,327 | Common Stock | |
| Apellis Pharmaceuticals Inc | J. Townsend Adam | Chief Commercial Officer | 01 Dec 2023 | 42,443 | 76,407 (0%) | 0% | 61.3 | 2,601,977 | Common Stock | |
| Unicycive Therapeutics Inc | John W. Townsend | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2023 | 570,329 | 647,190 | - | - | Stock Options | |
| Gogo Inc | Charles C. Townsend | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 3,527 | 151,227 | - | - | Deferred Share Units | |
| VIZIO Holding Corp Ordinary | Adam Townsend | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2023 | 155,360 | 579,672 | - | 0 | Class A Common Stock |